MarketCap
Facebook
X
Telegram
KalVista Pharmaceuticals Accounts Payables | KALV
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables KalVista Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.27 M | 9.11 M | 4.82 M | 3.64 M | 1.98 M | 1.68 M | 2.86 M | 1.43 M | 1.15 M | 1.01 M | 1.46 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.11 M | 1.01 M | 3.4 M |
Quarterly Accounts Payables KalVista Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.04 M | 8.07 M | 5.87 M | 4.88 M | 5.73 M | 5.2 M | - | 9.11 M | 3.1 M | 4.9 M | 5.06 M | 4.82 M | 2.18 M | 3.38 M | 2.91 M | 3.64 M | 641 K | 3.16 M | 1.45 M | 1.98 M | 2.95 M | 2.17 M | 1.77 M | 1.68 M | 3 M | 2.24 M | 3.1 M | 2.86 M | 1.58 M | 3.02 M | 2.34 M | 1.43 M | 755 K | 1.04 M | 1.94 M | 1.15 M | - | 431 K | 187 K | 793 K | 1.46 M | 1.53 M | 1.46 M | 1.46 M | 1.02 M | 1.02 M | 1.02 M | 1.02 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.11 M | 187 K | 2.8 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
4.39 M | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Allakos
ALLK
|
5.49 M | - | - | $ 28.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
579 K | $ 1.88 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
27.3 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
2.61 M | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
1.76 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
32.8 M | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.16 M | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
10.1 M | - | - | $ 384 M |  Britain |
 |
Genocea Biosciences
GNCA
|
500 K | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
124 K | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
858 K | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
1.55 M | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Cerus Corporation
CERS
|
28 M | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
3.99 M | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
9.92 M | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.18 M | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
610 K | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
Cellectar Biosciences
CLRB
|
1.44 M | $ 1.8 | 0.72 % | $ 4.69 M | USA |
 |
AbbVie
ABBV
|
3.59 B | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
40.5 M | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
890 K | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
Abeona Therapeutics
ABEO
|
7.89 M | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
10.7 M | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
40.4 M | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
IGM Biosciences
IGMS
|
983 K | - | - | $ 76.9 M | USA |
 |
Kinnate Biopharma
KNTE
|
2.03 M | - | - | $ 123 M | USA |
 |
Cardiff Oncology
CRDF
|
8.09 M | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
3.38 M | - | - | $ 231 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
2.22 M | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
6.78 M | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
5.61 M | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
7.88 M | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
22.6 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
11.1 M | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
 |
Champions Oncology
CSBR
|
6.9 M | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
3.94 M | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
2.49 M | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
3.95 M | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
1.06 M | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.17 M | $ 4.85 | 0.2 % | $ 929 M |  Canada |
 |
Cytokinetics, Incorporated
CYTK
|
22.3 M | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
1.2 M | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
2.88 M | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
1.48 M | $ 7.94 | 1.4 % | $ 373 M | USA |